Chemosaturation: A Novel Frontier For Liver Directed Therapy | 7621
ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Chemosaturation: A novel frontier for liver directed therapy

World Congress on Gastroenterology & Urology

Fred M. Moeslein

Key Note Forum: J Gastrointest Digest Sys

DOI: 10.4172/2161-069X-S1.01

After the lymph system, the liver is the primary site for metastatic disease regardless of origin. Importantly, progression of primary and metastatic liver disease is a major determinant both of quality of life and overall survival in these patients. There are numerous locoregional therapies, ranging from ablative techniques, embolization based techniques and infusional therapies. Chemosaturation using the Percutaneous Hepatic Perfusion technique (CS-PHP) offers a truly novel approach to the treatment of diffuse hepatic neoplastic disease. In this therapy, a high dose chemotherapeutic agent is administered via the Hepatic artery, and then the non-absorbed agent is filtered from the blood stream via an extracorporeal circuit before it is returned to the patient. This technique allows for very high dose delivery of cytotoxic agents to the liver parenchyma while protecting the systemic tissues from toxic exposure. The results from the Phase III clinical trial which evaluated CS-PHP for the treatment of metastatic ocular melanoma will be presented, as well as future directions for this exciting therapy